Is ‘vaping illness’ a sign British American Tobacco’s future is going up in smoke? 

British American Tobacco plc (LSE:BATS) is an excellent dividend stock for income-seeking investors. However, concerns about the health risks of e-cigarettes could be denting the company’s growth story.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Big Tobacco has had an incredible run. Its products were always addictive and easy to manufacture. Over time, as the health risks of smoking became undeniable, governments across the world opted to clamp down and tightly regulate the industry rather than ban the products altogether. 

The confluence of these factors made the tobacco industry one of the most concentrated and profitable industries on the planet. The aggregate profits for all major tobacco producers across the world exceeded US$62.27bn (£49.6bn) in 2015, the latest year with full records. 

In 2016, the five largest producers shipped 2.27tn cigarettes, which equates to more than 300 units for every human alive at the time. One of those large producers is London-based British American Tobacco (LSE:BATS), which reported £9.3bn in operating income last year.

Like other Big Tobacco leaders, BAT has managed to avoid death and taxes to create profits. A steady decline in the number of smokers in the developed world has been offset by a growing number of new smokers in emerging markets, particularly Asia. 

However, the industry understands that growth in the Asian market will eventually saturate like the rest of the world, which is why they have turned to a new source of potential growth – e-cigarettes, or vapes. 

These vaping products, or ‘new category’ products as BAT likes to call them, accounted for more than £1.8bn in sales last year. The company cut 2,300 staff earlier this year and has initiated a restructuring to focus on this segment and to double the sales of vaping-related items by 2024.  

Investors were so thrilled by the company injecting some fresh blood into its already lucrative business that they pushed the stock up by nearly a third earlier this year. 

However, I believe it’s too early for this sort of optimism. Not much is known about the long-term health consequences of vaping, and this year we started to see signs that this innovative new category may not be the panacea tobacco investors were hoping for. 

According to the Centers for Disease Control and Prevention (CDC), a new form of lung disease linked to the use of vaping products has already claimed eight lives and affected 530 people across the US. This week, Canada reported its first official case of vaping illness, when a teenager was put on life support. By Wednesday, the Indian government had announced a blanket ban on all vaping products across the country.

I wouldn’t be surprised if more cases and more bans emerged in the years ahead. Governments may be compelled to step in and nip this issue in the bud. That could mean BAT’s hopes of growth could be going up in smoke.

Nonetheless, BAT is far from being a doomed company or a bad investment, in my opinion. As I mentioned in my previous article, more than a billion people are still addicted to tobacco and could help cover the 7% dividend yield BAT currently offers, for decades to come. 

Foolish takeaway

I believe BAT is still an excellent dividend stock for income-seeking investors. However, concerns about the health risks of e-cigarettes could be denting the company’s growth story.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

VisheshR has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »